<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895930</url>
  </required_header>
  <id_info>
    <org_study_id>AST-PMR2002</org_study_id>
    <nct_id>NCT04895930</nct_id>
  </id_info>
  <brief_title>Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC</brief_title>
  <acronym>FOCUS-A</acronym>
  <official_title>A Multi-center, One-arm Clinical Trial of Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allist Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this phase Ⅱ study is to evaluate the efficacy and safety of Furmonertinib&#xD;
      combined with Anlotinib as the first-line treatment in locally advanced or metastatic&#xD;
      non-small cell lung cancer with sensitive EGFR mutations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Approximately 3 years following the first dose of study drugs</time_frame>
    <description>Proportion of subjects whose tumors were assessed as complete response(CR) or partial response(PR) according to RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Approximately 3 years following the first dose of study drugs</time_frame>
    <description>Proportion of subjects whose tumors were assessed as CR, PR or stable disease (SD) according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Approximately 3 years following the first dose of study drugs</time_frame>
    <description>The time from objective tumor remission (CR or PR) to the progression of the disease or death for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression free survival (PFS)</measure>
    <time_frame>Approximately 3 years following the first dose of study drugs</time_frame>
    <description>The time from the first does of the study drugs to the progression of the disease or death for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Until 30 days from the last dose of study drugs or initiation of a new anticancer treatment</time_frame>
    <description>Number of participants with adverse events as a measure of safety and tolerability.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-Small-Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Furmonertinib Plus Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Furmonertinib (80mg) plus Anlotinib (10mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furmonertinib</intervention_name>
    <description>80mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (40mg).</description>
    <arm_group_label>Furmonertinib Plus Anlotinib</arm_group_label>
    <other_name>AST2818</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>10mg/day orally from day 1 to 14 of a 21-day cycle. If subjects suffer from AEs, they can get declined dosage (8mg).</description>
    <arm_group_label>Furmonertinib Plus Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects have voluntarily participated, signed and dated informed consent;&#xD;
&#xD;
          2. Male or female subjects aged ≥18 and ≤75 years old;&#xD;
&#xD;
          3. Locally advanced or metastatic adenocarcinoma NSCLC confirmed by histology or cytology&#xD;
             (according to the 8th Edition of the AJCC Staging system), not suitable for surgery or&#xD;
             radiotherapy;&#xD;
&#xD;
          4. ECOG score 0-1, and life expectancy no less than 12 weeks according to the&#xD;
             investigator's assessment;&#xD;
&#xD;
          5. The tumour harbours one of the most common EGFR mutations (19del or L858R) ;&#xD;
&#xD;
          6. According to RECIST 1.1, subjects have at least one measurable tumor lesion at&#xD;
             baseline, and had not received radiotherapy previously;&#xD;
&#xD;
          7. No previous systemic anti-tumor therapy for locally advanced or metastatic NSCLC. For&#xD;
             recurrent disease, adjuvant therapy or neoadjuvant therapy may be accepted, but&#xD;
             recurrence occurs ≥6 months from stopping treatment;&#xD;
&#xD;
          8. Subjects with stable clinical symptoms of pleural effusion or ascites after&#xD;
             symptomatic treatment;&#xD;
&#xD;
          9. For premenopausal women with fertility, the result of serum or urine pregnancy test&#xD;
             should be negative within 7 days before the first dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not lung adenocarcinoma, including lung squamous carcinoma, or mixed histology, etc;&#xD;
&#xD;
          2. Subjects are expected to participate in other clinical studies during this trial&#xD;
             period;&#xD;
&#xD;
          3. Imaging evidence showed that the tumor had invaded critical blood vessels;&#xD;
&#xD;
          4. Subjects who receive systemic anti-tumor therapy used for locally advanced or&#xD;
             metastatic NSCLC previously;&#xD;
&#xD;
          5. With other malignant tumors at present or history of other malignant tumors within 5&#xD;
             years;&#xD;
&#xD;
          6. Leptomeningeal metastases or central nervous system metastasis requiring emergency&#xD;
             treatment;&#xD;
&#xD;
          7. At the beginning of study treatment, any unresolved toxic reaction to prior treatment&#xD;
             (e.g., adjuvant chemotherapy) exceeds CTCAE Grade 1;&#xD;
&#xD;
          8. History of ILD, drug-induced ILD, radiation pneumonitis which require steroid&#xD;
             treatment, or with suspected clinical manifestations of ILD or high risk factors;&#xD;
&#xD;
          9. Severe gastrointestinal dysfunction may affect the intake, transport or absorption of&#xD;
             the study drugs;&#xD;
&#xD;
         10. Recent active digestive diseases or other conditions that may cause gastrointestinal&#xD;
             bleeding or perforation;&#xD;
&#xD;
         11. Presence of bleeding constitution or active bleeding; any bleeding event ≥CTCAE grade&#xD;
             3, unhealed wounds, ulcers, or fractures occurred within 28 days prior to the first&#xD;
             dose;&#xD;
&#xD;
         12. Any of the following organ function criteria is met (no blood or blood product&#xD;
             transfusions, no hematopoietic stimulating factors, no albumin or blood product&#xD;
             transfusions within 7 days prior to examination): Absolute value of neutrophil&#xD;
             (NE)&lt;1.5 × 109/L, platelet (PLT) count&lt;90 × 109/L, hemoglobin (HGB)&lt;90 g/L; Serum&#xD;
             total bilirubin (TBIL)&gt;1.5 × ULN, aspartate aminotransferase (AST) and/or alanine&#xD;
             aminotransferase (ALT)&gt;2.5 × ULN (for liver metastases or Gilbert Syndrome, TBIL&gt;3 ×&#xD;
             ULN, and AST and/or ALT&gt;5 × ULN); Serum creatinine (SCr)&gt;1.5 × ULN, or creatinine&#xD;
             clearance&lt;60ml/min. (According to the Cockcroft and Gault formula); Urinary protein ≥&#xD;
             ++, or 24-hour urine protein&gt;1.0g; International normalized ratio（INR）&gt;1.5 and&#xD;
             activated partial thromboplastin time (APTT)&gt;1.5 ULN; Fasting blood glucose &gt;10mmol/L；&#xD;
&#xD;
         13. Any of the following cardiac criteria is met：&#xD;
&#xD;
               -  At rest, the mean corrected QT interval (QTc) by ECG &gt; 470 msec；&#xD;
&#xD;
               -  Seriously abnormal of heart rhythm, conduction, or morphology of resting ECG;&#xD;
&#xD;
               -  Any factors that may increase the risk of prolonged QTc or risk of arrhythmic&#xD;
                  events;&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) &lt; 50%;&#xD;
&#xD;
               -  Uncontrollable hypertension (systolic blood pressure≥150 mmHg and/or diastolic&#xD;
                  blood pressure≥100 mmHg);&#xD;
&#xD;
         14. With active infection diseases, such as HBV, HCV and HIV;&#xD;
&#xD;
         15. Known or suspected to be allergic to Furmonertinib and Anlotinib and / or other&#xD;
             components of their preparations;&#xD;
&#xD;
         16. Pregnancy or lactation;&#xD;
&#xD;
         17. Subjects who are considered ineligible for the study for other reasons according to&#xD;
             the investigator's assessment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Baohui Han, MD</last_name>
    <phone>+86 021-22200000</phone>
    <email>songzh100@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baohui Han</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Shi Y, Hu X, Zhang S, Lv D, Wu L, Yu Q, Zhang Y, Liu L, Wang X, Cheng Y, Ma Z, Niu H, Wang D, Feng J, Huang C, Liu C, Zhao H, Li J, Zhang X, Jiang Y, Gu C. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respir Med. 2021 Aug;9(8):829-839. doi: 10.1016/S2213-2600(20)30455-0. Epub 2021 Mar 26.</citation>
    <PMID>33780662</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Baohui Han</investigator_full_name>
    <investigator_title>Director of department</investigator_title>
  </responsible_party>
  <keyword>EGFR mutations; furmonertinib; anlotinib; non-squamous NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflutinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

